These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18722865)

  • 41. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
    Evans WK
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status of vinorelbine for breast cancer.
    Smith GA
    Oncology (Williston Park); 1995 Aug; 9(8):767-73; discussion 774, 776, 779. PubMed ID: 7577376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
    Hillner BE; Smith TJ
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
    Ellis P; Davies AM; Evans WK; Haynes AE; Lloyd NS;
    J Thorac Oncol; 2006 Jul; 1(6):591-601. PubMed ID: 17409924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy of malignant pleural mesothelioma.
    Bertino P; Carbone M; Pass H
    Expert Opin Pharmacother; 2009 Jan; 10(1):99-107. PubMed ID: 19236184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
    Stebbing J; Powles T; McPherson K; Shamash J; Wells P; Sheaff MT; Slater S; Rudd RM; Fennell D; Steele JP
    Lung Cancer; 2009 Jan; 63(1):94-7. PubMed ID: 18486273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review on clinical trials of targeted treatments in malignant mesothelioma.
    Jakobsen JN; Sørensen JB
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):1-15. PubMed ID: 21553148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma.
    Fracasso PM; Tan BR; Grieff M; Stephenson J; Liapis H; Umbeck NL; Von Hoff DD; Rowinsky EK
    J Natl Cancer Inst; 1999 Oct; 91(20):1779-80. PubMed ID: 10528031
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemotherapy for malignant mesothelioma.
    Baas P
    Lung Cancer; 2005 Jul; 49 Suppl 1():S61-4. PubMed ID: 15950803
    [No Abstract]   [Full Text] [Related]  

  • 50. Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
    Kumar N; Alrifai D; Kolluri KK; Sage EK; Ishii Y; Guppy N; Borg E; Falzon M; Nankivell M; Nicholson AG; Janes SM
    Lung Cancer; 2019 Jan; 127():164-166. PubMed ID: 30642545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic treatment of malignant pleural mesothelioma.
    Grosso F; Scagliotti GV
    Future Oncol; 2012 Mar; 8(3):293-305. PubMed ID: 22409465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
    Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
    Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vinorelbine--a clinical review.
    Gregory RK; Smith IE
    Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
    [No Abstract]   [Full Text] [Related]  

  • 54. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
    Kubota K
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
    Bellmunt J; Delgado FM; George C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update: vinorelbine (navelbine) in non-small cell lung cancer.
    Crawford J
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):2-7. PubMed ID: 8610232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
    van Meerbeeck J; Debruyne C; van Zandwijk N; Postmus PE; Pennucci MC; van Breukelen F; Galdermans D; Groen H; Pinson P; van Glabbeke M; van Marck E; Giaccone G
    Br J Cancer; 1996 Sep; 74(6):961-3. PubMed ID: 8826866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
    Hada M; Kazuhiro M
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2191-4. PubMed ID: 15628770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.
    Zauderer MG
    Nat Commun; 2021 Mar; 12(1):1819. PubMed ID: 33753750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intracavitary therapies for mesothelioma.
    Verschraegen CF
    Curr Treat Options Oncol; 2001 Oct; 2(5):385-94. PubMed ID: 12057101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.